http://rdf.ncbi.nlm.nih.gov/pubchem/reference/325919

Outgoing Links

Predicate Object
contentType Clinical Trial|Clinical Trial, Phase II|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't|Research Support, U.S. Gov't, P.H.S.
endingPage 204
issn 1432-0843
0344-5704
issueIdentifier 2
pageRange 199-204
publicationName Cancer Chemotherapy and Pharmacology
startingPage 199
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_f5e1b534e1a50c55ee64be57d4d13aa1
bibliographicCitation Goodin S, Rao KV, Kane M, Dave N, Capanna T, Doyle-Lindrud S, Engle E, Jin L, Todd M, DiPaola RS. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer. Cancer Chemother Pharmacol. 2005 Aug;56(2):199–204. doi: 10.1007/s00280-004-0980-1. PMID: 15838657.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_95f80ccfc8b9a2addd9f023b317a3a6b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_080caeca367a86cf460b27143f34b4f1
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7f6888f92cd40b100a36911bad3c33f4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fc32b99785d2ed29a40c94a23dd46963
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1d90312be68496934979103aa79fb133
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_71a0e04890dd9bb3d37677d3c3a922c8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4a44e26f66de615bda3e83766d91d6f4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0a9df0b96298f70a89728b1b3bf0cecc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8ef31ca8c5ebe71ad4f973d5e4260881
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b30f625e7274dd7cf18856d59148d29f
date 2005-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1007/s00280-004-0980-1
https://pubmed.ncbi.nlm.nih.gov/15838657
isPartOf https://portal.issn.org/resource/ISSN/1432-0843
https://portal.issn.org/resource/ISSN/0344-5704
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2664
language English
source https://www.crossref.org/
https://scigraph.springernature.com/
https://pubmed.ncbi.nlm.nih.gov/
title A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer
discusses http://id.nlm.nih.gov/mesh/M0028300
http://id.nlm.nih.gov/mesh/M0022672
http://id.nlm.nih.gov/mesh/M0184558
http://id.nlm.nih.gov/mesh/M0443608
http://id.nlm.nih.gov/mesh/M0097344
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID73265388
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60780
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6795
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5672
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5743
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID44424639
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5995
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID46931011
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_f762fe2442e70fe54d540f3fd4225b55
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5865
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71296871
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fce276cc0efd2412c7dafdbb1e82fcc8
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13200033
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11445
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10516
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5311497
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4212

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136123131
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129159660
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129717275
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128397534

Total number of triples: 61.